Philadelphia Business Journal by John George, Senior Reporter
BioBehavioral Diagnostics Co. raised $5.2 million in a private stock sale, according to documents filed with the Securities & Exchange Commission.
The Plymouth Meeting, Pa., company had developed and markets a tool —originally incorporated into a kiosk-like setup — that objectively measures brain functions to assist health-care providers diagnose attention-deficit hyperactivity disorder.
Last year, I wrote about the BioBehavioral Diagnostic’s development of a portable version of its Quotient ADHD System that is designed to take up less space in an office and be taken to different locations.
The system involves patients taking a 15- to 20-minute test designed to measure inattention, or the ability to focus; hyperactivity, the inability to sit still; and impulsivity, or acting without thinking.
Those factors are key elements used in the diagnosis of ADHD, a condition that affects nearly 10 million children, adolescents and adults in the United States.
The test consists of flashing images of stars on a screen. Patients are asked to hit the space bar when certain types of stars appear, and do nothing when other types of stars are shown. Reflectors worn on a headband and around the shins measure the results.
BioBehavioral Diagnostics is led by Byron Hewett, chairman and CEO.
The equity financing was disclosed in a filing provided to the Philadelphia Business Journal by FormsD.com.
